ScaleReady announces a G-Rex® Grant has been awarded to Dr. Eric Tran of the Earle A. Chiles Research Institute, a division of Providence Cancer Institute

Core Insights - ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady, announced the awarding of a $200,000 G-Rex Grant to Dr. Eric Tran for the development of a novel KRAS-targeted TCR-T cell therapy [1][2] Company and Industry Overview - The G-Rex Grant will significantly reduce costs associated with bringing the next generation TCR-T cell therapy into clinical trials, specifically targeting solid tumors in a Phase 1/1b clinical trial [2] - Dr. Tran aims to optimize the manufacturing process by reducing duration and implementing fully-closed system G-Rex bioreactors, utilizing Bio-Techne's GMP cytokines tailored for efficient manufacturing [3] - ScaleReady's G-Rex Grant Program is a $20 million initiative aimed at advancing cell and gene-modified cell therapy (CGT) development, offering individual grants up to $300,000 [4] - The G-Rex manufacturing platform is currently utilized by over 800 organizations, producing drug products for approximately 50% of CGT clinical trials and five commercially approved CGT drugs [5] - Companies leveraging ScaleReady's expertise can expect to save significant time and costs in the commercialization of CGT [6] - Wilson Wolf is focused on simplifying CGT therapy research and manufacturing through its scalable G-Rex technology, which is widely used in various CGT applications [7] - Bio-Techne Corporation provides innovative tools and reagents for research and clinical diagnostics, partnering with Wilson Wolf to create products tailored for G-Rex Bioreactors [8] - CellReady is the first G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based CGT development and manufacturing [9]